Ingevity (NGVT)
(Delayed Data from NYSE)
$42.00 USD
+0.21 (0.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $42.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.00 USD
+0.21 (0.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $42.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum C VGM
Zacks News
Ingevity Corporation (NGVT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 0.74% and -3.52%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICL vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity (NGVT) Up 20% in a Year: What's Driving the Stock?
by Zacks Equity Research
Let's take a look into the factors that are working in Ingevity's (NGVT) favor.
ICL or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
ICL or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Why Is Ingevity Corporation (NGVT) Down 13.3% Since Last Earnings Report?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ICL vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity's (NGVT) Earnings Beat Estimates in Q1, Sales Lag
by Zacks Equity Research
Ingevity (NGVT) gained from the addition of the engineered polymers product line in Q1. The company reaffirmed its guidance for 2019.
Ingevity Corporation (NGVT) Tops Q1 Earnings Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 4.21% and -0.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
DowDuPont (DWDP) Gears Up for Q1 Earnings: What's in Store?
by Anindya Barman
DowDuPont's (DWDP) Agriculture unit faces challenges from the impact of bad weather conditions in Q1.
What's in Store for Scotts Miracle-Gro (SMG) in Q2 Earnings?
by Zacks Equity Research
Scotts Miracle-Gro's (SMG) fiscal Q2 results to benefit from growth in the Hawthorne segment.
CF Industries (CF) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
CF Industries (CF) to benefit from higher demand of nitrogen fertilizers in Q1.
U.S. Steel (X) Warms Up to Q1 Earnings: What's in the Cards?
by Anindya Barman
U.S. Steel (X) will likely witness some pressure on shipment volumes in the first quarter.
Can Arconic (ARNC) Maintain Earnings Beat Streak in Q1?
by Zacks Equity Research
Arconic (ARNC) will likely gain from strong momentum across its major end-markets in Q1.
Can Global Industrial Unit Fuel Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Expected sales growth across segments, product innovation and accelerating pricing are likely to aid Ecolab (ECL) in Q1. However, forex might play spoilsport.
Ingevity Corporation (NGVT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ingevity Corporation (NGVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for LyondellBasell (LYB) in Q1 Earnings?
by Zacks Equity Research
While LyondellBasell (LYB) faces headwinds from maintenance outages and pressure on olefin margins, it should gain from the A. Schulman buyout in Q1.
What's in the Cards for Freeport (FCX) This Earnings Season?
by Zacks Equity Research
Higher unit net cash costs for copper is likely to affect Freeport's (FCX) performance in Q1.
Is a Beat in Store for Cleveland-Cliffs (CLF) in Q1 Earnings?
by Nilanjan Gupta
Cleveland-Cliffs expects (CLF) weak price and tonnage in Q1 results.
Air Products (APD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Air Products' (APD) Industrial Gases - Americas unit is expected to benefit from higher volumes in Q2 earnings. However, lower activity from the Jazan project is a concern for the Global segment.
What's in Store for Eastman Chemical (EMN) in Q1 Earnings?
by Zacks Equity Research
While Eastman Chemical (EMN) faces input cost pressure, it should gain from productivity actions and growth of high margin products in Q1.
Is a Beat in Store for Sherwin-Williams' (SHW) Q1 Earnings?
by Zacks Equity Research
Sherwin-Williams' (SHW) Q1 results to benefit from cost-control initiatives and synergies of the Valspar acquisition.
Celanese (CE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Our proven model does not show that Celanese (CE) is likely to beat estimates this quarter.
Nucor (NUE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Lower sheet prices will likely hurt Nucor's (NUE) results in the first quarter.